Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometabolic conditions are Scribe’s initial focus as the biotech works to bring genetic medicines beyond rare diseases.
The post CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO appeared first on MedCity News.
Google gives developers an AI bug hunter that also writes patches
Google has launched a preview of CodeMender, an AI agent built to scan code for security flaws, confirm they are exploitable, and generate fixes for
